RNA U2 small nuclear 6, pseudogene (RNU2-6P)

**RNU2-6P** (RNA U2 small nuclear 6, pseudogene) is a **pseudogene** related to the U2 small nuclear RNA (snRNA) gene family, which encodes components of the spliceosomal complex critical for pre-mRNA splicing in eukaryotes[1][2][3]. The U2 snRNA is a core RNA element within the spliceosome, directly involved in the recognition of intron branch sites and in catalyzing RNA splicing reactions. However, *RNU2-6P* itself is classified as a **pseudogene**—a non-functional genomic DNA sequence originally derived from a functional U2 snRNA gene but containing mutations or truncations that prevent the production of a functional snRNA molecule.\n\n**Context and Supporting Details:**\n- The term "pseudogene" means this is **not a protein-coding gene nor a functional receptor, enzyme, transporter, or other druggable target**[1][3].\n- Pseudogenes like RNU2-6P are often the result of retrotranspositional events or gene duplication followed by mutational inactivation[3].\n- While the canonical U2 snRNA is essential for mRNA processing and is implicated in various diseases and splicing-related mechanisms[1][2], pseudogenes such as RNU2-6P are typically **not biologically active** and have no known **therapeutic, biomarker, or drug-interacting roles**[1][3].\n- No current evidence links RNU2-6P specifically to disease, biomarker use, or drug interaction.\n\n**Key Points:**\n- **RNU2-6P is not considered a therapeutic target, and is not functionally active**[1][3].\n- There is nothing inherently wrong with the name, but it is **not a drug target; it is a non-functional pseudogene**.\n- All relevant biological and disease roles, drug interactions, and mechanisms of action pertain to the functional U2 snRNA, not to this pseudogene.\n\n**Summary Statement:** \nRNU2-6P is a pseudogene derived from the U2 small nuclear RNA gene family, is not a therapeutic target, and does not have relevant biological or clinical function.

Other names

RNU2-6PU2 snRNA pseudogene 6U2-6P